Sutro Biopharma Inc (STRO) Stock Price, Quote & News

Company Profile

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneu...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 881 6500

Fax: 650 553 9659

Website: www.sutrobio.com

Address:

111 Oyster Point Boulevard, South San Francisco, United States

NVDAMillionaire Sep. 8 at 12:21 PM

$STRO Excellent article that nails exactly where STRO stands right now. So if you want to update your STRO knowledge or get acquainted with STRO, this is a must read. https://beyondspx.com/quote/STRO/analysis/sutro-biopharma-xpresscf-platform-powers-a-focused-oncology-pipeline-resurgence-nasdaq-stro

0 · Reply

KY3000 Sep. 7 at 3:51 PM

$STRO 004 might be an underdog, benchmarked to Pfizer TF ADC, will have data to compare to. Better safety profile at minimum will make it a contender

1 · Reply

KY3000 Sep. 6 at 5:04 PM

$STRO spinoff/or sell as a package , 002,003, and 006=100$MILL minimum. Every sutro collab involves share purchases, Astellas has made none.

0 · Reply

KY3000 Sep. 6 at 4:57 PM

$STRO not mentioned in WF, maybe 2027 approval of VAX 31=60$MILL. With RFK drama, it’s time for vaxcyte to explore redo/new targets for all vaccines.

0 · Reply

KY3000 Sep. 6 at 4:54 PM

$STRO listened to WF. 004 is benchmarked against Pfizer TF ADC(currently phase 3), 004 has been dosed up to 50 mg a kg, compared to 3mg a kg. Fully funded to initiate 3 IND. Astellas milestone 6-9 months(Chow)

0 · Reply

unearthedmosquito Sep. 5 at 9:52 PM

$STRO Why has it up over 30% this week? any news? or is it really undervalued?

0 · Reply

Zaksab Sep. 5 at 3:45 PM

$STRO clearly something is afoot. the buying has been too keen for a while to suggest otherwise.

1 · Reply

Duskfall Sep. 5 at 3:45 PM

$STRO 👍

1 · Reply

KY3000 Sep. 4 at 5:16 PM

$STRO RFK is an environmental lawyer. This is insane

0 · Reply

KY3000 Sep. 3 at 9:49 PM

$STRO biotech rally is all about RFK senate hearing. A Leash or PR so bad trump fires him.

0 · Reply

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:31 PM EDT - 4 months ago

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 1, 2025, 4:05 PM EDT - 4 months ago

Sutro Biopharma to Participate in Upcoming Investor Conferences

Apr 28, 2025, 4:05 PM EDT - 5 months ago

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Mar 15, 2025, 6:40 PM EDT - 6 months ago

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Mar 14, 2025, 12:09 PM EDT - 6 months ago

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Mar 13, 2025, 4:07 PM EDT - 6 months ago

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Mar 13, 2025, 4:05 PM EDT - 6 months ago

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Mar 3, 2025, 4:05 PM EST - 7 months ago

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Jan 7, 2025, 4:05 PM EST - 9 months ago

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 6:28 PM EST - 9 months ago

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Nov 13, 2024, 4:30 PM EST - 10 months ago

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 4, 2024, 4:05 PM EST - 11 months ago

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Nov 1, 2024, 8:00 AM EDT - 11 months ago

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Oct 10, 2024, 4:05 PM EDT - 1 year ago

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sep 23, 2024, 12:46 PM EDT - 1 year ago

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 20, 2024, 4:01 PM EDT - 1 year ago

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 14, 2024, 3:00 AM EDT - 1 year ago

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Aug 22, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Jun 3, 2024, 10:00 AM EDT - 1 year ago

VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline

May 13, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

Apr 5, 2024, 6:31 PM EDT - 1 year ago

Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors

Apr 2, 2024, 6:18 AM EDT - 1 year ago

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Apr 2, 2024, 1:00 AM EDT - 1 year ago

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Mar 25, 2024, 4:30 PM EDT - 1 year ago

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jan 4, 2024, 4:05 PM EST - 1 year ago

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Dec 29, 2023, 4:11 PM EST - 1 year ago

Sutro: Luveltamab Data At ESMO Signifies Continued ADC Advancement

Dec 14, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

$Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023$

Dec 11, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

Dec 4, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Nov 21, 2023, 4:05 PM EST - 1 year ago

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Nov 13, 2023, 4:30 PM EST - 2 years ago

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Oct 22, 2023, 4:25 AM EDT - 2 years ago

Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023

Oct 16, 2023, 4:05 PM EDT - 2 years ago

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

Oct 9, 2023, 9:48 AM EDT - 2 years ago

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Sep 14, 2023, 1:21 PM EDT - 2 years ago

Sutro BioPharma: Good Stewardship Through Early Trials

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Jun 3, 2023, 4:00 PM EDT - 2 years ago

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

May 31, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma to Participate in the Jefferies Healthcare Conference

May 15, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

May 8, 2023, 8:00 AM EDT - 2 years ago

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Apr 27, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Apr 18, 2023, 1:30 PM EDT - 2 years ago

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

Apr 11, 2023, 1:17 PM EDT - 2 years ago

Sutro: Too Little, Too Late For STRO-002, But Platform Is Interesting

Mar 30, 2023, 4:30 PM EDT - 2 years ago

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

NVDAMillionaire Sep. 8 at 12:21 PM

0 · Reply

KY3000 Sep. 7 at 3:51 PM

$STRO 004 might be an underdog, benchmarked to Pfizer TF ADC, will have data to compare to. Better safety profile at minimum will make it a contender

1 · Reply

KY3000 Sep. 6 at 5:04 PM

$STRO spinoff/or sell as a package , 002,003, and 006=100$MILL minimum. Every sutro collab involves share purchases, Astellas has made none.

0 · Reply

KY3000 Sep. 6 at 4:57 PM

$STRO not mentioned in WF, maybe 2027 approval of VAX 31=60$MILL. With RFK drama, it’s time for vaxcyte to explore redo/new targets for all vaccines.

0 · Reply

KY3000 Sep. 6 at 4:54 PM

0 · Reply

unearthedmosquito Sep. 5 at 9:52 PM

$STRO Why has it up over 30% this week? any news? or is it really undervalued?

0 · Reply

Zaksab Sep. 5 at 3:45 PM

$STRO clearly something is afoot. the buying has been too keen for a while to suggest otherwise.

1 · Reply

Duskfall Sep. 5 at 3:45 PM

$STRO 👍

1 · Reply

KY3000 Sep. 4 at 5:16 PM

$STRO RFK is an environmental lawyer. This is insane

0 · Reply

KY3000 Sep. 3 at 9:49 PM

$STRO biotech rally is all about RFK senate hearing. A Leash or PR so bad trump fires him.

0 · Reply

Zaksab Sep. 3 at 8:33 PM

$STRO somewhat intruiging move

1 · Reply

B_man6969 Sep. 3 at 2:21 PM

$STRO wow

0 · Reply

Flok5000 Sep. 2 at 6:00 PM

$STRO seems different today… had multiple times in last weeks strong gains in the beginning but lost most at the end of the day.

1 · Reply

theBigDollarski Sep. 2 at 1:58 PM

$STRO Hollah!!!

0 · Reply

unearthedmosquito Sep. 2 at 1:55 PM

$STRO whats happening right now ?

0 · Reply

Zaksab Sep. 2 at 1:49 PM

$STRO something afoot?

0 · Reply

WhatGoesOn Sep. 2 at 11:58 AM

$STRO In 2 weeks, we’re coming on 6 months below $1. STRO runs the real risk of being kicked out NASDAQ. Why isn’t the SP tanking?

1 · Reply

KY3000 Aug. 30 at 3:43 PM

$STRO it’s time for someone to commercialize 002 and bring 003 thru trial, dual payload milestones for any 002/003 targets. Spinoff or Sale. With 002 &003 , I support a spinoff soon if no sale this year. Mid/low FRA ovarian are unmet needs, AbbVie/genahamb litigation will delay RA-S. My opinion

0 · Reply

KY3000 Aug. 30 at 3:32 PM

$STRO San Carlo (sutro)& Boehringer ( using sutro tech), are the only commercial scale cellfree ADC companies. Boehringer made 4500L, makes around 9k-11k doses, wind down of clinical trials of 002 has to be fully dosed

0 · Reply

KY3000 Aug. 30 at 3:17 PM

$STRO vax31 phase 3 initiation soon. 60$ mill milestone still owed. Ipsen/merck still own -+ 9mill shares.

0 · Reply

KY3000 Aug. 30 at 3:13 PM

$STRO “winding down clinical trials”, means STRO still has ongoing trials for 002, data coming for the phase 1 combo/ phase 3 FRA

0 · Reply

OhTheHorror Aug. 29 at 2:31 PM

$STRO In 2 weeks, we’re coming on 6 months below $1. STRO runs the real risk of being kicked out NASDAQ. Why isn’t the SP tanking?

0 · Reply

Market Cap	74.34M
Revenue (ttm)	62.04M
Net Income (ttm)	-227.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-366.63%
Debt to Equity Ratio	0.00

Volume	309,512
Avg Vol	490,588
Day's Range	N/A - N/A
Shares Out	84.77M
Stochastic %K	7%
Beta	1.57
Analysts	Sell
Price Target	$2.68